Navigation Links
Antibody Engineering Company f-star Appoints Three Pioneers in Antibody Engineering and Development to its Newly Established Scientific Advisory Board
Date:12/12/2007

VIENNA, Austria, December 12 /PRNewswire/ -- f-star, an antibody engineering company developing novel antibodies and antibody fragments based on its unique Modular Antibody Technology, announced today that it has established a Scientific Advisory Board and has appointed three outstanding scientists to form the nucleus of this advisory body. Members of f-star's Scientific Advisory Board include:

Professor Sir Ravinder Maini, Imperial College, London, UK

Sir Ravinder Maini is Emeritus Professor of Rheumatology at Imperial College, University of London, UK, and currently a member of the Trust Board of The Kennedy Institute of Rheumatology, London. He is a pioneer in the research and development of anti-TNF therapy, played a vital role in research and clinical development of infliximab (Remicade), and was a non-Executive Director of Domantis, the antibody engineering company founded in 2000 and acquired by GSK in 2006.

Professor Anthony Rees, MIP Technologies AB, Lund, Sweden

Anthony Rees is CEO of MIP Technologies AB, a company developing molecularly imprinted polymers. He was previously Scientific Director at the French biotech company Synt:em and before that Head of the School of Biology and Biochemistry at the University of Bath, UK. In 1989, Dr Rees was scientific co-founder of Oxford Molecular plc which marketed antibody modelling software developed by his group at Universities of Oxford and Bath, now available as a web-based modelling service and widely used in antibody engineering.

Professor Sir Gregory Winter, MRC Laboratory of Molecular Biology, Cambridge, UK

Sir Gregory Winter is Deputy Director of the Medical Research Council's Laboratory of Molecular Biology and Head of the Division of Protein and Nucleic Acids Chemistry. Sir Gregory developed technologies for making human antibodies, and most of the therapeutic antibodies on the market were developed using methods devised by him. He was a founder and Director of Cambridge Antibody Technology, now part of MedImmune, AstraZeneca's biologics business unit. In 2000 he co-founded Domantis, recently acquired by GSK, and acted as Director and Chairman of the Scientific Advisory Board.

"We are enthusiastic and feel highly privileged that these pioneers in antibody engineering and development will support us in our mission to develop next generation therapeutics based on our Modular Antibody Technology", said Gottfried Himmler, Chief Executive Officer, f-star. "Their in-depth experience and advice will be an invaluable asset in our efforts to build f-star into a major player in the next generation antibody field."

About f-star

f-star is an antibody engineering company based in Vienna, Austria. The Company develops improved therapeutic antibodies and antibody fragments based on its Modular Antibody Technology, which allows the introduction of additional binding sites into antibodies and antibody fragments by engineering the non-CDR loops of constant or variable domains. Modular Antibody Technology allows for the creation of antibody fragments with antibody functionality and long half-life but much smaller size (Fcab(TM)) or full antibodies with additional functionality (mAb squared).

The Company was founded by a team of highly experienced antibody engineering and biotech executives. Seed-financed by Austrian government agencies and Atlas Venture in 2006, the Company raised EUR 9.0m in a Series A financing round from Aescap Venture, Atlas Venture and Novo A/S in 2007. In total, the Company has raised more than EUR 13m so far.
For more information, visit http://www.f-star.com

Company contact:

Dr. Eugen Stermetz

CFO

f-star Biotechnologische Forschungs- und Entwicklungs-GmbH

+43-72055-4215

Gastgebgasse 5-13

A-1230 Vienna, Austria

http://www.f-star.com

office@f-star.com

Media contact:

Frank Butschbacher

Investor Relations & Communications

+43-650-78-44-940

office@butschbacher.net

http://www.butschbacher.net


'/>"/>
SOURCE f-star
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Medimmune announces phase 2 safety data for anti-RSV antibody and national RSV surveillance results
2. Antibody leads to repair of myelin sheath in lab study of multiple sclerosis and related disorders
3. Antibody Helps Repair MS Nerve Damage
4. Ono and Medarex Announce Allowance of Investigational New Drug Application for Fully Human Anti-PD1 Antibody
5. ThromboGenics Begins Preclinical Development of Anti-VPAC Antibody for Thrombocytopenia
6. Antibody responses in patients with Lyme arthritis
7. Micromet and MedImmune to Present New Clinical Data for Anti-CD19 BiTE(R) Antibody at American Society of Hematology Annual Meeting Showing Objective Clinical Responses in Relapsed Non-Hodgkins Lymphoma Patients
8. Panacea Pharmaceuticals Announces Selection of PAN-622 - A Fully Human Sequence Monoclonal Antibody Against HAAH - As Its Lead Cancer Therapeutic Product
9. MSU engineering team designs innovative medical device
10. Specialty Blades, Inc. Expands Management Team With New VP Engineering
11. McGraw-Hill Professional Enhances Library Access to Medical and Engineering Resources
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/23/2017)... ... April 23, 2017 , ... ... services announced the achievement of Cisco Select certification and SMB specialization. Altura ... States. , In earning the Select Certification, Altura fulfilled the training ...
(Date:4/22/2017)... ... ... Juan Capistrano summer camp team at the Boys and Girls Club of South Coast ... physical activities for all campers. To read the report, click here or see ... specialty camps that focus on what the report terms as “sitting subjects” like coding or ...
(Date:4/21/2017)... ... April 21, 2017 , ... Chicago plastic surgeon, ... of osteoma. An osteoma is a benign bony lump located on the forehead usually ... can cause difficulties with sight and pain. Dr. Shah has discovered an approach that ...
(Date:4/21/2017)... ... April 21, 2017 , ... The adage “Show, don’t ... the next project in the company’s esteemed VISION House demonstration project series. Manifesting the ... the amount of resources they need to live affordably and abundantly without unduly taxing ...
(Date:4/21/2017)... , ... April 21, 2017 , ... ... weeklong campaign, AWARE: A Week of Addiction and Recovery Education, from April 24 ... treating and preventing substance use disorders. , The mission of AWARE is ...
Breaking Medicine News(10 mins):
(Date:4/18/2017)... , April 18, 2017 Cogentix Medical, ... on providing the Urology, Uro/Gyn and Gynecology markets with ... the first quarter ended March 31, 2017 after the ... The Company will host a conference call and ... on Tuesday, May 2, 2017 at 4:30 p.m. Eastern ...
(Date:4/18/2017)... , April 18, 2017 Research and ... Market 2017-2021" report to their offering. ... The global arthroscopy devices market to grow at a ... report, Global Arthroscopy Devices Market 2017-2021, has been prepared based on ... covers the market landscape and its growth prospects over the coming ...
(Date:4/18/2017)... DIEGO and BLOOMINGTON, Minn. ... Inc. (NASDAQ: IMMY ) ("Imprimis"), an ... Precision Lens ("Precision Lens"), today announced the signing ... the agreement, Precision Lens will deploy a dedicated ... select geographies in the U.S., primarily focused in ...
Breaking Medicine Technology: